Guru Ray Dalio (Trades, Portfolio) added 140,400 shares of Gilead Sciences Inc. (GILD, Financial), a research-based biopharmaceutical company that discovers, develops and markets innovative medicines, to his portfolio in the third quarter.
This was a 171.80% increase for Dalio, who now owns 222,121 shares of Gilead.
Pioneer Investments added 9,128 Gilead shares to its portfolio in the third quarter. The purchase was a 0.28% increase in Pioneer Investments' holding. It now owns 3,283,529 company shares.
Pioneer Investments was founded by Philip L. Carret in 1928. He started out investing $10,000 into common stocks, and his investment grew into $8 million over the course of 55 years. Warren Buffett (Trades, Portfolio) once said Carret had "the best long-term investment record of anyone I know."
Dalio founded Bridgewater Associates in 1975 from scratch as he was starting his family. Today Bridgewater Associates is the world's biggest hedge fund firm, managing $155 billion according to Forbes.com.
Gilead Sciences' mission is to care for people with life-threatening illnesses around the world. Gilead Sciences primarily focuses on drugs that include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Gilead Sciences has a market cap of $148.08 billion, a P/E ratio of 9.42, an enterprise value of $157.82 billion, a P/S ratio of 5.04 and a Quick ratio of 2.56.
Below is a Peter Lynch Chart for Gilead Sciences.
Dalio and Pioneer Investments are adding Gilead Sciences to their portfolios because:
- The book value has been growing by an average of 22% over the past 10 years.
- The operating margin is expanding. Gilead Sciences is expanding in size, usually a good sign.
- Gilead Sciences is doing good things for the world by conducting research to cure and help people with life-threatening illnesses.
Gilead is also traded in Germany, Chile and Switzerland.
(Disclaimer: The author does not currently hold any shares of Gilhead Sciences.)
Cheers to your investment success.
